Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery
He Tang, Lin Wang, Tianyu Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115607-115607
Closed Access | Times Cited: 23

Showing 23 citing articles:

Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives
Fei Wen, Gang Gui, Xiaoyu Wang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 99, pp. 117595-117595
Closed Access | Times Cited: 9
Discovery of dual PARP/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer
Jie Mao, Kaizhen Wang, Jun Tong, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130117-130117
Closed Access | Times Cited: 1
Effects of quercetin and derivatives on NAMPT/Sirtuin-1 metabolic pathway in neuronal cells: an approach to mitigate chemotherapy-induced cognitive impairment
Jeena John, Subham Das, Anil Philip Kunnath, et al.
Metabolic Brain Disease (2025) Vol. 40, Iss. 3
Open Access
Mechanisms of resistance to NAMPT inhibitors in cancer
Jansen Redler, Ariana E. Nelson, Christine M. Heske
Cancer Drug Resistance (2025)
Open Access
The Role of Visfatin in Gastric and Esophageal Cancer: From Biomarker to Therapeutic Target
Adam Mylonakis, Alexandros Kozadinos, Maximos Frountzas, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1377-1377
Open Access
Discovery of Potent PDEδ/NAMPT Dual Inhibitors: Preclinical Evaluation in KRAS Mutant Pancreatic Cancer Cells
Yaojin Zhu, Zhenqian Chen, Guoyuan Wu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy
Fikriye Ozgencil, Habibe Beyza Gunindi, Gökçen Eren
Bioorganic Chemistry (2024) Vol. 149, pp. 107509-107509
Closed Access | Times Cited: 3
Single-cell RNA sequencing explores the evolution of the ecosystem from leukoplakia to head and neck squamous cell carcinoma
Haibin Wang, Zhenjie Guan, Lian Zheng
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Pre-existing cancer cells and induced fibroblasts are key cells for early chemoresistance in ovarian cancer
Langyu Gu, Shasha He, Linxiang Wu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma
Chunjia Yin, Shuting Jia, Xiaojuan Yang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116444-116444
Closed Access | Times Cited: 1
Identification and validation of drugs for repurposing in Glioblastoma: a computational and experimental workflow
Nazareno González, Melanie Pérez Küper, Matías Garcia Fallit, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
NAMPT Overexpression Drives Cell Growth in Polycystic Liver Disease through Mitochondrial Metabolism Regulation
Kishor Pant, Sergio A. Gradilone
American Journal Of Pathology (2024) Vol. 194, Iss. 8, pp. 1528-1537
Closed Access | Times Cited: 1
Targeting NAD Metabolism: Rational Design, Synthesis and In Vitro Evaluation of NAMPT/PARP1 Dual-Target Inhibitors as Anti-Breast Cancer Agents
Yingpeng Li, Xianxiu Kong, Xinhong Chu, et al.
Molecules (2024) Vol. 29, Iss. 12, pp. 2836-2836
Open Access | Times Cited: 1
NAMPT enhances LOX expression and promotes metastasis in human chondrosarcoma cells by inhibiting miR‐26b‐5p synthesis
Chih‐Yang Lin, Yat‐Yin Law, Cheng‐Chieh Yu, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 9
Closed Access | Times Cited: 1
Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers
Subin Myong, Anh Nguyen, Sridevi Challa
Cancers (2024) Vol. 16, Iss. 17, pp. 3085-3085
Open Access | Times Cited: 1
Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment
Mengyuan Ding, Qianqian Shen, Wei Lü, et al.
Molecular Diversity (2023) Vol. 28, Iss. 4, pp. 2617-2636
Open Access | Times Cited: 3
Enrichment of a neutrophil-like monocyte transcriptional state in glioblastoma myeloid suppressor cells
John K. Wiencke, Emily Nissen, Devin C. Koestler, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents
Irene Conforti, Andrea Benzi, Irene Caffa, et al.
Medicinal Chemistry (2024) Vol. 20, Iss. 7, pp. 694-708
Closed Access
Identification and validation of drugs for repositioning in Glioblastoma: a computational and experimental workflow
Nazareno González, Melanie Pérez Küper, Matías Garcia Fallit, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination
Michael Gruet, Yitao Xu, Lin-Ying An, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Recent Advances in Tumor Metabolism: Illuminating Novel Pathways in Cancer Research
Zubair Ahmad, Abdur Rauf
Journal Of Biochemical Technology (2024) Vol. 15, Iss. 4, pp. 1-2
Closed Access
Differential Mitochondrial Redox Responses to the Inhibition of NAD+ Salvage Pathway of Triple Negative Breast Cancer Cells
Jack Kollmar, Junmei Xu, Diego Gonzalves, et al.
Cancers (2024) Vol. 17, Iss. 1, pp. 7-7
Open Access
Drug Discovery Targeting Nicotinamide Phosphoribosyltransferase (NAMPT): Updated Progress and Perspectives
Fei Wen, Gang Gui, Xiaoyu Wang, et al.
(2023)
Closed Access
Page 1

Scroll to top